Reviving A Longsuffering Neuro Company: The Marinus Story

Marinus Pharmaceuticals’ CEO spoke candidly to In Vivo about breathing new life into ultra-rare epilepsy disorder drug ganaxolone.    

Phoenix flying high
Marinus' phoenix has now risen from the ashes • Source: Shutterstock

When Marinus Pharmaceuticals, Inc.’ Ztalmy (ganaxolone) CV was approved by the FDA in March 2022 for seizures associated with a rare, genetic pediatric onset epilepsy disorder, nobody was more elated than CEO Scott Braunstein. Having come out of retirement to advance the development of the positive allosteric modulator of the GABAA receptor – which had previously failed in clinical trials for Fragile X syndrome and post-partum depression – this was a make-or-break moment for the company and the drug.

Ztalmy, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients two years of age and older, is thought to make peak US sales of around $92m, according to H.C Wainwright

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from In Vivo